TWi Biotechnology, Inc.

TWi Biotechnology, Inc. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan, founded in 2010. The company specializes in the research and development of innovative drugs targeting innate immunity-related diseases, with a particular focus on rare conditions. Its development pipeline includes candidates such as AC-203, under Phase 2 clinical trials for various skin and autoimmune disorders (including epidermolysis bullosa simplex and gout), and AC-1101, which is progressing through early-stage trials for diseases like vitiligo and atopic dermatitis. TWi Biotechnology operates with a strategy of drug repositioning, aiming to address unmet medical needs where current treatment options are limited or insufficient. The company’s collaboration agreements enable extension of its products into broader regional markets, such as Mainland China and Hong Kong. Through its targeted approach, TWi Biotechnology plays a significant role within the healthcare and biotechnology sectors, contributing to advancements in therapies for both common and rare immune-mediated diseases.